The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress.


Creative Commons License

PARLAR A., Arslan S. O. , Dogan M. F. , Cam S. A. , Yalcin A., Elibol E., ...Daha Fazla

Experimental and therapeutic medicine, cilt.16, ss.4900-4908, 2018 (SCI Expanded İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 16 Konu: 6
  • Basım Tarihi: 2018
  • Doi Numarası: 10.3892/etm.2018.6753
  • Dergi Adı: Experimental and therapeutic medicine
  • Sayfa Sayıları: ss.4900-4908

Özet

The present study aimed to investigate the role of cannabinoid 2 (CB2) receptors in a rat model of acute inflammation. Therefore, the potential of anti-inflammatory effects of CB2 receptor agonist (GW405833), CB2 receptor antagonist (AM630), and diclofenac, were investigated in carrageenan induced paw oedema in rats: as were assessed by measuring paw oedema; myeloperoxidase (MPO) activity in paw tissue; malondialdehyde (MDA) concentration; glutathione (GSH) level in paw tissue for oxidant/antioxidant balance; cytokine (interleukin-1, IL-1; tumour necrosis factor-, TNF-) levels in serum; histopathology of paw tissue for inflammatory cell accumulations. The results showed that GW405833 or diclofenac significantly reduced carrageenan-induced paw oedema. GW405833 also inhibited the increase of MPO activity, the recruitment of total leukocytes and neutrophils, and MDA concentration during carrageenan-induced acute inflammation, along with reversed nearly to the normal levels the increased of TNF-, and IL-1 in serum. AM630 did not affect inflammation alone however clearly reversed the effects of agonist when co-administered. The mechanism of GW405833's suppression of inflammation is supported by these results, which are achieved by the inhibition of neutrophil migration, which regulates the reduction of oxidative stress, TNF- and IL-1 levels. Finally, the activation of CB2 receptor, by selective agonist, has a major role in peripheral inflammation, and in the near future, targeting the peripheral cannabinoid system as a promising alternative to treat inflammation diseases may be considered a novel pharmacologic approach.